The inability to target Aβ in AD therapy and the intractability of neurodegenerative diseases have led many researchers to focus their research on tau protein, and many basic studies have demonstrated that the knockdown or inhibition of tau can reduce tau-associated pathological effects; thus, drugs targeting tau protein have attracted increasing attention. This evidence concerns the gene MAPT and neurodegenerative disease.